EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 3.0

Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study

Myriam Calle Rubio iD, Juan Antonio Trigueros Carrero iD, Paula Chaparro Briones iD, Luciano Escudero Herrera, Michael Pollack iD, Ignacio Hernández Subirá, Joaquín Sánchez-Covisa iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s490227 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Myriam Calle Rubio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pneumology Service, H. Clínico San Carlos. Institute for Health Research (IdISSC), Department of Medicine, Complutense University, CIBER de Enfermeda…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Formoterol Fumarate, Bronchodilator Agents, Glycopyrrolate. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveFormoterol FumarateBronchodilator AgentsGlycopyrrolateLungBudesonideAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsHumansMaleFemaleAgedRetrospective StudiesSpainMiddle AgedTreatment OutcomeAdministration, InhalationDrug CombinationsTime FactorsSeverity of Illness IndexAged, 80 and overDrug Therapy, Combination

Stichwörter der Autor:innen

budesonide/glycopyrronium/formoterolchronic obstructive pulmonary diseaseexacerbationsreal-world datasingle-inhaler triple therapy

Substanzen

Formoterol FumarateBronchodilator AgentsGlycopyrrolateBudesonideAdrenergic beta-2 Receptor AgonistsDrug CombinationsMuscarinic Antagonists

Autor:innen und Institutionen

  • Pneumology Service, H. Clínico San Carlos. Institute for Health Research (IdISSC), Department of Medicine, Complutense University, CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Sp…
  • Buenavista Primary Care Center, Toledo, Spain.
  • AstraZeneca Farmacéutica Spain, Madrid, Spain.
  • AstraZeneca, LP. BioPharmaceuticals Medical, Wilmington, DE, USA.
  • Atrys Health SA, HEOR, Madrid, Spain.

ORCID-Profile: Myriam Calle Rubio, Juan Antonio Trigueros Carrero, Paula Chaparro Briones, Michael Pollack, Joaquín Sánchez-Covisa

Zitieren

APA

Calle Rubio, M., Trigueros Carrero, J. A., Chaparro Briones, P., Escudero Herrera, L., Pollack, M., Hernández Subirá, I., & Sánchez-Covisa, J. (2025). Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s490227

Vancouver

Calle Rubio M, Trigueros Carrero JA, Chaparro Briones P, Escudero Herrera L, Pollack M, Hernández Subirá I, et al. Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s490227

BibTeX
@article{CalleRubio2025,
  author = {Calle Rubio, Myriam and Trigueros Carrero, Juan Antonio and Chaparro Briones, Paula and Escudero Herrera, Luciano and Pollack, Michael and Hernández Subirá, Ignacio and Sánchez-Covisa, Joaquín},
  title = {Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s490227}
}
Kostenlos starten →